After chemoradiation, 57% of stage III lung cancer patients are dead within five years1.

Two thirds have progressed.2 Stage III accounts for roughly a quarter of all non-small cell diagnoses.3

More than half of stage III lung cancer patients die within five years of treatment given with the intent to cure. That fraction is what we are here to change.

Please note: Nyxeris Bio operates in a stealth capacity.

Someone on the team reads every message. Details are held only so that we can answer. Privacy policy.